FDA panel votes for more data before approval of AstraZeneca drug
June 25, 2014 at 14:51 PM EDT
June 25 (Reuters) - An advisory panel to the U.S. Food and Drug Administration recommended on Wednesday that AstraZeneca Plc be required to submit further clinical data before its experimental ovarian cancer drug is approved.
